ATE269848T1 - Calciumkanalblocker als antikrebsmittel - Google Patents

Calciumkanalblocker als antikrebsmittel

Info

Publication number
ATE269848T1
ATE269848T1 AT00921867T AT00921867T ATE269848T1 AT E269848 T1 ATE269848 T1 AT E269848T1 AT 00921867 T AT00921867 T AT 00921867T AT 00921867 T AT00921867 T AT 00921867T AT E269848 T1 ATE269848 T1 AT E269848T1
Authority
AT
Austria
Prior art keywords
anticancer
calcium channel
channel blockers
compounds
directed
Prior art date
Application number
AT00921867T
Other languages
English (en)
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE269848T1 publication Critical patent/ATE269848T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00921867T 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel ATE269848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12814399P 1999-04-07 1999-04-07
PCT/US2000/009310 WO2000059882A1 (en) 1999-04-07 2000-04-07 Anticancer calcium channel blockers

Publications (1)

Publication Number Publication Date
ATE269848T1 true ATE269848T1 (de) 2004-07-15

Family

ID=22433855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921867T ATE269848T1 (de) 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel

Country Status (6)

Country Link
EP (1) EP1165508B1 (de)
JP (1) JP4932994B2 (de)
AT (1) ATE269848T1 (de)
CA (1) CA2369588C (de)
DE (1) DE60011755T2 (de)
WO (1) WO2000059882A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410871A (pt) * 2003-05-30 2006-07-04 Neuromed Tech Inc 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
CA2576186A1 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
EP2073799A4 (de) * 2007-03-12 2009-08-19 Vm Discovery Inc Neuartige wirkstoffe aus kalziumionenkanalmodulatoren
KR101601332B1 (ko) 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
EP3106166B1 (de) 2008-02-29 2020-12-02 VM Therapeutics LLC Substanzen zur behandlung von schmerzsyndrom und anderen leiden
EP2268665B1 (de) 2008-03-19 2014-11-12 Soricimed Biopharma Inc. Peptidzusammensetzung zur krebstherapie durch inhibieren der trpv6-kalziumkanalaktivität
EP2350002A1 (de) 2008-10-02 2011-08-03 Abbott Laboratories Neue verbindungen als kalziumkanalblocker
CN102292319A (zh) 2008-11-26 2011-12-21 雅培制药有限公司 作为钙通道阻滞剂的取代八氢环戊二烯并(c)吡咯-4-胺
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
US8815869B2 (en) 2010-03-18 2014-08-26 Abbvie Inc. Lactam acetamides as calcium channel blockers
WO2011149995A1 (en) 2010-05-25 2011-12-01 Abbott Laboratories Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
WO2011149993A2 (en) 2010-05-25 2011-12-01 Abbott Laboratories SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
WO2013049164A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
UY34349A (es) 2011-09-29 2013-04-05 Abb Vie Inc OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
AU2013359533A1 (en) 2012-12-12 2015-05-28 Abbvie, Inc. Diazepine derivatives useful as calcium channel blockers in the treatment of pain
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
EP3752149A4 (de) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. Chinolonanaloga und deren salze, zusammensetzungen und verfahren zu deren verwendung
CN115215800B (zh) * 2021-04-21 2023-07-18 赣江中药创新中心 一种二苯并环基-环胺基醚衍生物或盐及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2454092A (en) * 1947-06-02 1948-11-16 Parke Davis & Co Benzhydryl amino ethers
US2708194A (en) * 1952-12-10 1955-05-10 Univ Michigan 2-(1-methyl) polymethyleniminylmethyl benzhydryl ethers and preparation thereof
GB833807A (en) * 1957-07-10 1960-04-27 Beecham Res Lab Benzhydryl ethers
US3732247A (en) * 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
GB1307255A (en) * 1970-09-12 1973-02-14 Pfizer Ltd Substituted basic benzhydryl ethers
FR2601366B1 (fr) * 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
FR2636946B1 (fr) * 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
GB9000301D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
IE912759A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5981539A (en) * 1995-09-15 1999-11-09 Neurosearch A/S Piperidine compounds as calcium channel blockers
CA2204082A1 (en) * 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
JPH1135483A (ja) * 1997-05-20 1999-02-09 Nippon Kayaku Co Ltd 頻尿又は尿失禁の治療剤又は予防剤

Also Published As

Publication number Publication date
CA2369588A1 (en) 2000-10-12
JP2002541142A (ja) 2002-12-03
JP4932994B2 (ja) 2012-05-16
DE60011755D1 (de) 2004-07-29
DE60011755T2 (de) 2005-06-30
EP1165508A1 (de) 2002-01-02
CA2369588C (en) 2011-02-08
WO2000059882A1 (en) 2000-10-12
WO2000059882A9 (en) 2001-11-29
EP1165508B1 (de) 2004-06-23

Similar Documents

Publication Publication Date Title
DE60011755D1 (de) Calciumkanalblocker als antikrebsmittel
NZ506329A (en) Inhibitors of phospholipase enzymes
AU9263101A (en) Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
PL360373A1 (en) Non-imidazole aryloxypiperidines as h3 receptor ligands
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
PT1313721E (pt) Ariloxialquilaminas nao imidazoles como ligandos de receptor h3
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
AU4820101A (en) Novel compounds for modulating cell proliferation
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60001850D1 (de) Chalcon coumarine
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DE602004012146D1 (en) Pyrazolopyrimidine
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
EE200300156A (et) Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine
ATE259886T1 (de) Ledergerben
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
DE60011677D1 (en) Tryptase-inhibitoren
SI1244614T1 (en) Tryptase inhibitors
DE602004004093D1 (de) Alkylierte iminodibenzyle als antioxidationsmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties